JOHN K. CLARKE - 26 Apr 2023 Form 4 Insider Report for aTYR PHARMA INC (LIFE)

Role
Director
Signature
Nancy E. Denyes, Attorney-In-Fact
Issuer symbol
LIFE
Transactions as of
26 Apr 2023
Transactions value $
$0
Form type
4
Filing time
28 Apr 2023, 16:54:51 UTC
Previous filing
28 Apr 2022
Next filing
19 May 2023
SEC
View on sec.gov

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction LIFE Common Stock Options Exercise +6,000 +43.5% 19,797 26 Apr 2023 Direct F1, F2, F3

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction LIFE Restricted Stock Unit Options Exercise $0 -6,000 -100% $0.000000* 0 26 Apr 2023 Common Stock 0 Direct F2, F4
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Represents shares acquired upon the vesting of restricted stock units (RSUs) granted to the Reporting Person on April 26, 2022.
F2 RSUs convert into common stock on a one-for-one basis.
F3 Includes 6,305 shares received as a pro-rata distribution on September 28, 2021 (the "Liquidating Distribution") from CHP II, L.P., in which the Reporting Person is a managing partner. In prior reports, the reporting person reported beneficial ownership of 108,083 shares of aTyr Pharma common stock held by CHP II, L.P., which are no longer held as of September 28, 2021 due to the Liquidating Distribution.
F4 The RSUs fully vested one year from the grant date which was April 26, 2022.